학술논문

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study
Document Type
Article
Author
Solomon, Joshua JDanoff, Sonye KWoodhead, Felix AHurwitz, ShelleyMaurer, RieGlaspole, IanDellaripa, Paul FGooptu, BibekVassallo, RobertCox, P GerardFlaherty, Kevin RAdamali, Huzaifa IGibbons, Michael ATroy, LaurenForrest, Ian ALasky, Joseph ASpencer, Lisa GGolden, JeffreyScholand, Mary BethChaudhuri, NaziaPerrella, Mark ALynch, David AChambers, Daniel CKolb, MartinSpino, CathieRaghu, GaneshGoldberg, Hilary JRosas, Ivan OHaynes-Harp, ShanaPoli, FernandoVidya, Coimbatore SreeBaron, Rebecca R.Clouser, TimothyDoyle, TracyMaeda, AnthonyHighland, Kristin B.Albayda, Jemima F.Collins, Sarah E.Suresh, Karthik S.Davis, John M.Limper, Andrew H.Amigues, IsabelEliopoulos, KristinaSwigris, Jeffery J.Humphries, StephenHuntwork, John C.Glynn, ChrisDuncan, Steve R.Danila, Maria I.Glassberg, Marilyn K.Oberstein, Elana M.Belloli, Elizabeth A.Briggs, LindaNagaraja, VivekCholewa, LindaDiFranco, DonnaGreen, EdwardLiffick, ChristieNaik, TanviMontas, GenevieveLebiedz-Odrobina, DorotaBissell, RebaWener, MarkLancaster, Lisa H.Crawford, Leslie J.Chan, KarmelaKaner, Robert J.Morris, AliciaWu, XiaopingKhalidi, Nader A.Ryerson, Christopher J.Wong, Alyson W.Fell, Charlene D.LeClercq, Sharon A.Hyman, MarkShapera, ShaneMittoo, ShikhaShaffu, ShireenGaffney, KarlWilson, Andrew M.Barratt, ShaneyGunawardena, HarshaHoyles, Rachel K.David, JoelKewalramani, NamrataMaher, Toby M.Molyneaux, Philip L.Kokosi, Maria A.Cates, Matthew J.Mandizha, MandizhaAshish, AbdulChelliah, GladstoneParfrey, HelenThillai, MuhunthanVila, JosephineFletcher, Sophie V.Beirne, PaulFavager, ClairBrown, JoDawson, Julie K.Ortega, Pilar RiveraHaque, SahenaWatson, PippaKhoo, Jun K.Symons, KarenYoussef, PeterMackintosh, John A.
Source
The Lancet Respiratory Medicine; January 2023, Vol. 11 Issue: 1 p87-96, 10p
Subject
Language
ISSN
22132600; 22132619
Abstract
Interstitial lung disease is a known complication of rheumatoid arthritis, with a lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety, tolerability, and efficacy of pirfenidone for the treatment of patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD).